BACKGROUND: Phosphodiesterase 4B (PDE4B) is a candidate gene for schizophrenia and affective disorders through its disruption by a chromosomal translocation in an individual with schizophrenia, its inhibition by the antidepressant rolipram, and its physical interaction with another key candidate, Disrupted in Schizophrenia (DISC1). OBJECTIVE: To determine the contribution made by PDE4B to the population risk of schizophrenia and bipolar disorder by carrying out a case-control association study. METHODS: Twenty-six tagging single nucleotide polymorphisms were selected across the PDE4B gene and genotyped in DNA samples from 386 schizophrenia cases, 368 bipolar disorder cases and 455 controls. MAIN RESULTS: Single single nucleotide polymorphisms and a resulting haplotype conferred a protective effect against schizophrenia in the female population. The haplotype result remained significant after correction for multiple testing (P=0.012). CONCLUSION: The observation that a PDE4B haplotype alters the genetic risk of schizophrenia in the Scottish population complements the known participation of this gene in biological processes associated with mental illness. Further studies are needed to replicate this finding and identify underlying sequence variants.
BACKGROUND: Phosphodiesterase 4B (PDE4B) is a candidate gene for schizophrenia and affective disorders through its disruption by a chromosomal translocation in an individual with schizophrenia, its inhibition by the antidepressant rolipram, and its physical interaction with another key candidate, Disrupted in Schizophrenia (DISC1). OBJECTIVE: To determine the contribution made by PDE4B to the population risk of schizophrenia and bipolar disorder by carrying out a case-control association study. METHODS: Twenty-six tagging single nucleotide polymorphisms were selected across the PDE4B gene and genotyped in DNA samples from 386 schizophrenia cases, 368 bipolar disorder cases and 455 controls. MAIN RESULTS: Single single nucleotide polymorphisms and a resulting haplotype conferred a protective effect against schizophrenia in the female population. The haplotype result remained significant after correction for multiple testing (P=0.012). CONCLUSION: The observation that a PDE4B haplotype alters the genetic risk of schizophrenia in the Scottish population complements the known participation of this gene in biological processes associated with mental illness. Further studies are needed to replicate this finding and identify underlying sequence variants.
Authors: Mahomi Kuroiwa; Gretchen L Snyder; Takahide Shuto; Atsuo Fukuda; Yuchio Yanagawa; David R Benavides; Angus C Nairn; James A Bibb; Paul Greengard; Akinori Nishi Journal: Psychopharmacology (Berl) Date: 2011-08-11 Impact factor: 4.530
Authors: Irina N Bespalova; Martina Durner; Benjamin P Ritter; Gary W Angelo; Enrique Rossy-Fullana; Jose Carrion-Baralt; James Schmeidler; Jeremy M Silverman Journal: Schizophr Res Date: 2010-09-26 Impact factor: 4.939
Authors: Joshua A Azevedo; Bradley S Carter; Fan Meng; David L Turner; Manhong Dai; Alan F Schatzberg; Jack D Barchas; Edward G Jones; William E Bunney; Richard M Myers; Huda Akil; Stanley J Watson; Robert C Thompson Journal: J Psychiatr Res Date: 2016-07-18 Impact factor: 4.791
Authors: Helen M Knight; Benjamin S Pickard; Alan Maclean; Mary P Malloy; Dinesh C Soares; Allan F McRae; Alison Condie; Angela White; William Hawkins; Kevin McGhee; Margaret van Beck; Donald J MacIntyre; John M Starr; Ian J Deary; Peter M Visscher; David J Porteous; Ronald E Cannon; David St Clair; Walter J Muir; Douglas H R Blackwood Journal: Am J Hum Genet Date: 2009-12 Impact factor: 11.025